Breaking News Instant updates and real-time market news.

VRTX

Vertex

$173.50

2.49 (1.46%)

05:33
09/12/19
09/12
05:33
09/12/19
05:33

Vertex announces new access agreement with Scotland for Orkambi, Symkevi

Vertex Pharmaceuticals announced that eligible cystic fibrosis patients living in Scotland will now have access to Orkambi and Symkevi in combination with ivacaftor following the signing of an access agreement. As part of the 5-year agreement Vertex has also committed to collecting real world data on these medicines that will support any future submissions to the Scottish Medicines Consortium.

  • 12

    Sep

  • 19

    Mar

VRTX Vertex
$173.50

2.49 (1.46%)

08/28/19
ARGS
08/28/19
NO CHANGE
Target $200
ARGS
Buy
Vertex offers attractive entry point, says Argus
Argus analyst Jasper Hellweg keeps his Buy rating and $200 price target on Vertex but notes that its recent stock price retreat has taken valuation below historical averages and offers a "favorable entry point". The analyst is positive on the company's current product line-up and deep pipeline focused on cystic fibrosis drugs, with an eye on the March 2020 FDA action date for its next-generation triple-combination CF therapy regimen.
08/28/19
PIPR
08/28/19
NO CHANGE
PIPR
Symdeko deaths in FDA database likely due to disease, says Piper Jaffray
08/28/19
PIPR
08/28/19
NO CHANGE
Target $230
PIPR
Overweight
Vertex drug not cited as cause of 30 deaths in FDA database, says Piper Jaffray
The FDA Adverse Events Reporting System Public Dashboard citing 30 deaths with Symdeko caused volatility today in shares of Vertex Pharmaceuticals, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. After accessing the website, the analyst says none of the 30 deaths specifically indicate Symdeko, "but rather appear to be due to underlying cystic fibrosis disease." As such, the FAERS report does not signify a unique problem with Symdeko or Vertex's TripleRx combination, which is under review at the FDA, contends Tenthoff. The "timing of this short rumor to be suspicious during a quiet, end of summer week," he adds. The analyst continues to forecast Vertex's total cystic fibrosis sales at $3.7B this year, growing to $5B in 2020 with the TripleRx launch. He reiterates an Overweight rating on the stock with a $230 price target. Vertex in late morning trading is up 1%, or $1.84, to $180.09.
09/03/19
GSCO
09/03/19
UPGRADE
Target $254
GSCO
Conviction Buy
Vertex upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter added Vertex Pharmaceuticals to his firm's Americas Conviction List while raising his price target for the shares to $254 from $226 and keeping a Buy rating on the name. Vertex is in the midst of a multi-year period of "rapid" margin expansion and earnings outperformance driven by growth of the legacy cystic fibrosis franchise and likely launch of VX-445 triple combination, which has a March 19 FDA action date, Richter tells investors in a research note. Further, the analyst believes investor attention should now shift to the company's emerging pipeline, where he sees a "significant opportunity" in the Phase 2-ready alpha-1 antitrypsin deficiency disorder program.

TODAY'S FREE FLY STORIES

ADBE

Adobe

$279.40

1.61 (0.58%)

05:44
10/16/19
10/16
05:44
10/16/19
05:44
Downgrade
Adobe rating change  »

Adobe downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 29

    Oct

  • 04

    Nov

FMC

FMC Corporation

$83.06

0.6 (0.73%)

05:32
10/16/19
10/16
05:32
10/16/19
05:32
Upgrade
FMC Corporation rating change  »

FMC Corporation upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

SUBCY

Subsea 7

$0.00

(0.00%)

05:32
10/16/19
10/16
05:32
10/16/19
05:32
Downgrade
Subsea 7 rating change  »

Subsea 7 downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

RBS

RBS

$5.82

0.38 (6.99%)

05:28
10/16/19
10/16
05:28
10/16/19
05:28
Upgrade
RBS rating change  »

RBS upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 24

    Oct

INOV

Inovalon

$15.04

0.2 (1.35%)

05:27
10/16/19
10/16
05:27
10/16/19
05:27
Initiation
Inovalon initiated  »

Inovalon initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$136.17

0.26 (0.19%)

05:26
10/16/19
10/16
05:26
10/16/19
05:26
Hot Stocks
Collins Aerospace, Lufthansa sign A380 main landing gear MRO agreement »

Collins Aerospace…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

HOLX

Hologic

$49.44

0.94 (1.94%)

05:25
10/16/19
10/16
05:25
10/16/19
05:25
Recommendations
Hologic analyst commentary  »

Hologic shares can keep…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

GLPG

Galapagos

$162.62

6.33 (4.05%)

05:24
10/16/19
10/16
05:24
10/16/19
05:24
Hot Stocks
Galapagos enters drug discovery research collaboration with HitGen »

HitGen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

EPAY

Bottomline Technologies

$40.79

0.34 (0.84%)

05:21
10/16/19
10/16
05:21
10/16/19
05:21
Hot Stocks
Bottomline Technologies, Currencycloud partnership selected by Hargenant Group »

Bottomline Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 11

    Dec

CVLT

Commvault

$45.22

-0.24 (-0.53%)

05:20
10/16/19
10/16
05:20
10/16/19
05:20
Recommendations
Commvault analyst commentary  »

Commvault SaaS offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 01

    Nov

AMZN

Amazon.com

$1,768.70

31.65 (1.82%)

05:19
10/16/19
10/16
05:19
10/16/19
05:19
Hot Stocks
AWS selected as preferred cloud provider by Old Mutual Limited »

Amazon Web Services, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 21

    Nov

WATT

Energous

$3.29

0.09 (2.81%)

05:16
10/16/19
10/16
05:16
10/16/19
05:16
Hot Stocks
Energous enters partnership with ZPower »

Energous announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECD

Tech Data

$111.41

1.86 (1.70%)

, APO

Apollo Global

$39.39

0.63 (1.63%)

05:15
10/16/19
10/16
05:15
10/16/19
05:15
Periodicals
Apollo offered to acquire Tech Data for $130 per share in cash, Reuters reports »

Apollo Global Management…

TECD

Tech Data

$111.41

1.86 (1.70%)

APO

Apollo Global

$39.39

0.63 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 07

    Nov

MOSC

Mosaic Acquisition

$10.29

0.005 (0.05%)

05:09
10/16/19
10/16
05:09
10/16/19
05:09
Initiation
Mosaic Acquisition initiated  »

Mosaic Acquisition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASMB

Assembly Biosciences

$9.30

0.3 (3.33%)

05:06
10/16/19
10/16
05:06
10/16/19
05:06
Initiation
Assembly Biosciences initiated  »

Mizuho starts Assembly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 30

    Oct

AVAV

AeroVironment

$57.14

0.02 (0.04%)

05:00
10/16/19
10/16
05:00
10/16/19
05:00
Upgrade
AeroVironment rating change  »

AeroVironment upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$17.65

0.2 (1.15%)

04:57
10/16/19
10/16
04:57
10/16/19
04:57
Upgrade
Pure Storage rating change  »

Pure Storage upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 17

    Dec

BOALY

Boral

$0.00

(0.00%)

04:56
10/16/19
10/16
04:56
10/16/19
04:56
Downgrade
Boral rating change  »

Boral downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Wedbush technology analyst to hold an analyst/industry webcast »

Technology Analyst…

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Wedbush technology analyst to hold an analyst/industry webcast »

Technology Analyst…

JCOM

j2 Global

$96.34

0.47 (0.49%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
j2 Global management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

  • 01

    Nov

  • 19

    Nov

AUY

Yamana Gold

$3.19

-0.1 (-3.04%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Yamana Gold management to meet with TD Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 25

    Oct

SCS

Steelcase

$18.15

0.29 (1.62%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Steelcase management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

TRVI

Trevi Therapeutics

$4.00

-0.55 (-12.09%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Trevi Therapeutics management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
FBN Securities cannabis analysts to hold a breakfast meeting »

Analysts host Chairman…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.